Table 1.
Baseline characteristics of the cohort.
| Variables | All patients (n = 18) |
|---|---|
| Demographics | |
| Male, n (%) | 9/18 (50) |
| Age, mean ± SD | 41.3 ± 16.4 |
| Comorbidities | |
| Coronary artery disease, n (%) | 2/18 (11.1) |
| Myocardial infarction, n (%) | 0/18 (0) |
| CABG, n (%) | 0/18 (0) |
| Chronic obstructive pulmonary disease, n (%) | 2/18 (11.1) |
| Chronic kidney disease/dialysis, n (%) | 1/18 (5.6) |
| Atrial fibrillation or atrial flutter, n (%) | 3/18 (16.7) |
| TIA/stroke, n (%) | 1/18 (5.6) |
| Diabetes mellitus, n (%) | 0/18 (0) |
| Smoker, n (%) | 3/18 (16.7) |
| Hypertension, n (%) | 2/18 (11.1) |
| Hyperlipidemia, n (%) | 2/18 (11.1) |
| Overweight, n (%) | 10/18 (55.6) |
| BMI kg/m2, mean ± SD | 26.2 ± 5.9 |
| Family history of cardiovascular disease, n (%) | 4/18 (22.2) |
| Hospital side parameters | |
| Cardiogenic shock at diagnosis, n (%) | 4/18 (22.2) |
| Pulmonary edema, n (%) | 0/18 (0) |
| Days of hospitalization, mean ± SD | 11.1 ± 9.7 |
| Drug treatment | |
| ACE inhibitors, n (%) | 9/18 (50) |
| ARNI, n (%) | 0/18 (0) |
| Aldosterone antagonist, n (%) | 3/18 (16.7) |
| ß blocker, n (%) | 12/18 (66.7) |
| Amiodarone, n (%) | 0/18 (0) |
| LVEF | |
| LVEF at index, mean ± SD (%) | 48.7 ± 19.3 |
| LVEF short-term, mean ± SD (%) | 49.7 ± 16.6 |
| LVEF long-term, mean ± SD (%) | 55 ± 13.1 |
SD, Standard deviation; CABG, coronary artery bypass grafting; TIA, transient ischaemic attack; LVEF, left ventricular ejection fraction; BMI, body-mass-index; COPD, Chronic obstructive pulmonary disease; ACE, angiotensin-converting-enzyme; ARNI, angiotensin-converting enzyme inhibitors.